Erratum: Novel insight into mutational landscape of head and neck squamous cell carcinoma (PLoS ONE (2014) 9: 3 (e93102) DOI: 10.1371/journal.pone.0093102);Novel insight into mutational landscape of head and neck squamous cell carcinoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Gaykalova, Daria A ^a   Mambo, Elizabeth ^b   Choudhary, Ashish ^b   Houghton, Jeffery ^b   Buddavarapu, Kalyan ^b   Sanford, Tiffany ^b   Darden, Will ^b   Adai, Alex ^b   Hadd, Andrew ^b   Latham, Gary ^b   Danilova, Ludmila V ^a   Bishop, Justin ^a   Li, Ryan J ^a   Westra, William H ^a   Hennessey, Patrick ^a   Koch, Wayne M ^a   Ochs, Michael F ^a   Califano, Joseph A ^a,c   Sun, Wenyue ^a,d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b ASURAGEN INC   (United States)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; NOTCH1 RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CEBPA GENE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FES GENE; FGFR3 GENE; GENE MUTATION; GENE SEQUENCE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NOTCH1 GENE; ONCOGENE; PAPILLOMAVIRUS INFECTION; PRIMARY TUMOR; SEQUENCE ANALYSIS; SMOKING; TP53 GENE; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; MUTATION;

EID: 84899880744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0233409     Document Type: Erratum

References (90)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA: a cancer journal for clinicians 55: 74-108. (Pubitemid 40372904)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
4. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. The New England journal of medicine 359: 1143-1154.
5. Psyrri A, Boutati E, Karageorgopoulou S (2011) Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines. Anticancer drugs 22: 586-590.
6. Scully C, Field JK, Tanzawa H (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral oncology 36: 404-413. (Pubitemid 30645974)
7. Ha PK, Califano JA (2006) Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. The lancet oncology 7: 77-82. (Pubitemid 43025396)
8. Smith IM, Mydlarz WK, Mithani SK, Califano JA (2007) DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. International journal of cancer Journal international du cancer 121: 1724-1728.
9. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, et al. (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer research 56: 2488-2492. (Pubitemid 26170679)
10. Demokan S, Chuang A, Suoglu Y, Ulusan M, Yalniz Z, et al. (2012) Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer. Head & neck 34: 1470-1475.
11. Okami K, Wu L, Riggins G, Cairns P, Goggins M, et al. (1998) Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer research 58: 509-511. (Pubitemid 28087415)
12. Poeta ML, Manola J, Goldenberg D, Forastiere A, Califano JA, et al. (2009) The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 7658-7665.
13. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, et al. (2001) Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clinical cancer research: an official journal of the American Association for Cancer Research 7: 3127-3134.
14. Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, et al. (1996) Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer research 56: 1146-1150. (Pubitemid 26065414)
15. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N (2008) Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. International journal of oncology 32: 101-111. (Pubitemid 351176067)
16. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, et al. (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer discovery 3: 761-769.
17. Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25: 4057-4065.
18. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24: 4170-4176.
19. Hardisson D (2003) Molecular pathogenesis of head and neck squamous cell carcinoma. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies 260: 502-508.
20. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
21. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
22. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, et al. (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer discovery 3: 770-781.
23. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, et al. (2014) Activation of the NOTCH Pathway in Head and Neck Cancer. Cancer research 74: 1091-1104.
24. Jain P, Kantarjian H, Cortes J (2013) Chronic myeloid leukemia: overview of new agents and comparative analysis. Current treatment options in oncology 14: 127-143.
25. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, et al. (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet 45: 279-284.
26. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, et al. (2013) Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome medicine 5: 49.
27. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research 39: D945-950.
28. Cooper GM (1982) Cellular transforming genes. Science 217: 801-806.
29. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
30. Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, et al. (2005) Control of MAPK signalling: from complexity to what really matters. Oncogene 24: 5533-5542. (Pubitemid 43119348)
31. Shao C, Tan M, Bishop JA, Liu J, Bai W, et al. (2012) Suprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma. PloS one 7: e48582.
32. Gaykalova D, Vatapalli R, Glazer CA, Bhan S, Shao C, et al. (2012) Dose-dependent activation of putative oncogene SBSN by BORIS. PloS one 7: e40389.
33. Harrison JC, Haber JE (2006) Surviving the breakup: the DNA damage checkpoint. Annual review of genetics 40: 209-235. (Pubitemid 44956785)
34. Elnaggar MM, Agersborg S, Sahoo T, Girgin A, Ma W, et al. (2012) BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease. Molecular cytogenetics 5: 23.
35. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, et al. (2010) A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC cancer 10: 101.
36. Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, et al. (2011) BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leukemia research 35: 598-603.
37. Tewhey R, Warner JB, Nakano M, Libby B, Medkova M, et al. (2009) Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nature biotechnology 27: 1025-1031.
38. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, et al. (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. The Journal of molecular diagnostics: JMD 15: 234-247.
39. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics 43: 491-498.
40. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research 20: 1297-1303.
41. Zhang Y, Hiraishi Y, Wang H, Sumi KS, Hayashido Y, et al. (2005) Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. International journal of cancer Journal international du cancer 117: 166-168.
42. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45: 478-486.
43. Nichols AC, Yoo J, Palma DA, Fung K, Franklin JH, et al. (2012) Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines. Archives of otolaryngology - head & neck surgery 138: 732-739.
44. Adams JM (2003) Ways of dying: multiple pathways to apoptosis. Genes & development 17: 2481-2495.
45. Astier AL, Xu R, Svoboda M, Hinds E, Munoz O, et al. (2003) Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood 101: 1118-1127. (Pubitemid 36139387)
46. MacFarlane M, Williams AC (2004) Apoptosis and disease: a life or death decision. EMBO reports 5: 674-678.
47. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, et al. (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. The Journal of biological chemistry 280: 32081-32089. (Pubitemid 41361813)
48. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40. (Pubitemid 32225829)
49. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, et al. (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22: 4757-4759. (Pubitemid 36976451)
50. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, et al. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679. (Pubitemid 28435584)
51. Ruckert F, Dawelbait G, Winter C, Hartmann A, Denz A, et al. (2010) Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PloS one 5: e12243.
52. Fry TJ, Mackall CL (2002) Interleukin-7: from bench to clinic. Blood 99: 3892-3904. (Pubitemid 35332024)
53. Nusse R (2005) Wnt signaling in disease and in development. Cell research 15: 28-32.
54. Chocarro-Calvo A, Garcia-Martinez JM, Ardila-Gonzalez S, De la Vieja A, Garcia-Jimenez C (2013) Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer. Molecular cell 49: 474-486.
55. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO journal 19: 3159-3167. (Pubitemid 30428195)
56. Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506-1507.
57. Rosnet O, Mattei MG, Marchetto S, Birnbaum D (1991) Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 9: 380-385.
58. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, et al. (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. The New England journal of medicine 360: 2719-2729.
59. Kihm AJ, Kong Y, Hong W, Russell JE, Rouda S, et al. (2002) An abundant erythroid protein that stabilizes free alpha-haemoglobin. Nature 417: 758-763. (Pubitemid 34640631)
60. Luzzatto L, Notaro R (2002) Haemoglobin's chaperone. Nature 417: 703-705.
61. Della Rocca GJ, Maudsley S, Daaka Y, Lefkowitz RJ, Luttrell LM (1999) Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases. The Journal of biological chemistry 274: 13978-13984.
62. Hill SJ, Baker JG, Rees S (2001) Reporter-gene systems for the study of G-protein-coupled receptors. Current opinion in pharmacology 1: 526-532. (Pubitemid 33593844)
63. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713.
64. Sun W, Zhou S, Chang SS, McFate T, Verma A, et al. (2009) Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 476-484.
65. McCormick F (1995) Ras-related proteins in signal transduction and growth control. Molecular reproduction and development 42: 500-506.
66. Losman JA, Kaelin WG, Jr. (2013) What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & development 27: 836-852.
67. Solt LA, May MJ (2008) The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunologic research 42: 3-18.
68. Schindler CW (2002) Series introduction. JAK-STAT signaling in human disease. The Journal of clinical investigation 109: 1133-1137.
69. Kent D, Copley M, Benz C, Dykstra B, Bowie M, et al. (2008) Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 1926-1930.
70. Kawamura J, Shimada Y, Komoto I, Okamoto H, Itami A, et al. (2005) Multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas in Japan. Oncol Rep 14: 47-52.
71. Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, et al. (2006) The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proceedings of the National Academy of Sciences of the United States of America 103: 1018-1023. (Pubitemid 43212214)
72. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, et al. (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer research 69: 3021-3031.
73. Moliterno AR, Hankins WD, Spivak JL (1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. The New England journal of medicine 338: 572-580. (Pubitemid 28114645)
74. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, et al. (2009) Neurofibromatosis type 2. Lancet 373: 1974-1986.
75. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, et al. (2000) Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103: 127-140.
76. Nutt SL, Vambrie S, Steinlein P, Kozmik Z, Rolink A, et al. (1999) Independent regulation of the two Pax5 alleles during B-cell development. Nature genetics 21: 390-395. (Pubitemid 29159575)
77. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, et al. (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proceedings of the National Academy of Sciences of the United States of America 102: 14344-14349. (Pubitemid 41429700)
78. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, et al. (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559-1561. (Pubitemid 34971004)
79. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, et al. (2010) miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). British journal of cancer 103: 877-884.
80. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, et al. (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature genetics 34: 148-150. (Pubitemid 36666923)
81. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, et al. (2012) A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481: 329-334.
82. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, et al. (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. The Journal of clinical endocrinology and metabolism 93: 682-687. (Pubitemid 351398539)
83. Shioda T, Lechleider RJ, Dunwoodie SL, Li H, Yahata T, et al. (1998) Transcriptional activating activity of Smad4: roles of SMAD hetero- oligomerization and enhancement by an associating transactivator. Proceedings of the National Academy of Sciences of the United States of America 95: 9785-9790.
84. Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, et al. (2010) Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nature medicine 16: 1429-1433.
85. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, et al. (2000) Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406: 1005-1009.
86. Stehelin D, Fujita DJ, Padgett T, Varmus HE, Bishop JM (1977) Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization. Virology 76: 675-684. (Pubitemid 8078766)
87. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, et al. (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nature genetics 21: 187-190. (Pubitemid 29070364)
88. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810. (Pubitemid 47266337)
89. Qiu W, Schonleben F, Thaker HM, Goggins M, Su GH (2006) A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma. Oncogene 25: 2937-2942. (Pubitemid 43739244)
90. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, et al. (2010) Genetic analysis of von Hippel-Lindau disease. Human mutation 31: 521-537.